E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.
Nicholas J. Short,Hagop M. Kantarjian,Susan O'Brien,Farhad Ravandi,Deborah A. Thomas,Guillermo Garcia-Manero,Naval Daver,Gautam Borthakur,Nitin Jain,Marina Konopleva,Koji Sasaki,Naveen Pemmaraju,Yesid Alvarado,Jovitta Jacob,Rebecca Garris,Philip A. Thompson,Jorge E. Cortes,Elias Jabbour +17 more
TL;DR: Inotuzumab ozogamicin is an anti-CD22 antibody-toxin conjugate that is effective in patients with relapsed/refractory ALL and given the poor tolerance of elderly pts to InO, the use of InO in elderly patients with poor tolerance is likely to be limited.
Journal Article
Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.
TL;DR: This roundtable monograph reviews key unmet needs in patients with CML related to disease management and treatment options and indicates which patients will benefit from which therapies.
Journal ArticleDOI
Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents
Guillermo Montalban Bravo,Elias Jabbour,Tapan M. Kadia,Farhad Ravandi,Zeev Estrov,Kiran Naqvi,Koji Sasaki,Kelly S. Chien,Graciela M. Nogueras González,Xiao Qin Dong,Stefan Faderl,Heather Schneider,Rosmy B. John,Hagop M. Kantarjian,Guillermo Garcia-Manero +14 more
TL;DR: CPX-351 is a liposomal formulation of cytarabine and daunorubicin approved for the treatment of pts with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with MDS related changes and the primary end point was to evaluate the safety and determine the maximum tolerated dose.
Journal ArticleDOI
Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy
Nicholas J. Short,Hind Rafei,Naval Daver,Hyunsoo Hwang,Jing Ning,Jorge E. Cortes,Jeffrey L. Jorgensen,Tapan M. Kadia,Courtney D. DiNardo,Sa A. Wang,Elias Jabbour,Uday R. Popat,Betul Oran,Marina Konopleva,Guillermo Garcia-Manero,Gautam Borthakur,Kapil N. Bhalla,Ghayas C. Issa,Hagop M. Kantarjian,Farhad Ravandi +19 more
TL;DR: HSCT after first salvage therapy was the strongest prognostic factor for CIR, RFS and OS (P<0.001 for all), and MRD negativity rate was higher in pts with higher baseline bone marrow blasts than in those who were MRD-positive and was not associated with any other pretreatment parameter.
Journal ArticleDOI
Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL)
Deborah A. Thomas,Susan O'Brien,Michael Rytting,Farhad Ravandi,Elias Jabbour,Alessandra Ferrajoli,Zeev Estrov,Guillermo Garcia-Manero,Jan A. Burger,William G. Wierda,Marina Konopleva,Michael Andreeff,Steven M. Kornblau,Srdan Verstovsek,Gautam Borthakur,Tapan M. Kadia,Rebecca Garris,Naveen Pemmaraju,Naval Daver,Nitin Jain,Jorge E. Cortes,Hagop M. Kantarjian +21 more
TL;DR: CNS prophylaxis can be successfully achieved with intrathecal chemotherapy treatments (IT) in conjunction with systemic chemotherapy inclusive of high-dose methotrexate (MTX) and/or high- dose cytarabine (ara-C) without use of radiation therapy (XRT).